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Abstract
Introduction: Hypoxia induced factors (HIFs) are at the heart of the adaptive mechanisms cancer cells must implement for
survival. HIFs are regulated by four hydroxylases; Prolyl hydroxylase (PHD)-1,-2,-3 and factor inhibiting HIF (FIH). We aimed
to investigate the prognostic impact of these oxygen sensors in NSCLC.
Methods: Tumor tissue samples from 335 resected stages I to IIIA NSCLC patients was obtained and tissue microarrays
(TMAs) were constructed. Hydroxylase expression was evaluated by immunohistochemistry.
Principal Findings: There was scorable expression for all HIF hydroxylases in tumor cells, but not in stroma. In univariate
analyses, high tumor cell expression of all the HIF hydroxylases were unfavorable prognosticators for disease-specific
survival (DSS); PHD1 (P=0.023), PHD2 (P=0.013), PHD3 (P=0.018) and FIH (P=0.033). In the multivariate analyses we found
high tumor cell expression of PHD2 (HR=2.03, CI 95% 1.20–3.42, P=0.008) and PHD1 (HR=1.45, CI 95% 1.01–2.10,
P=0.047) to be significant independent prognosticators for DSS. Besides, there was an additive prognostic effect by the
increasing number of highly expressed HIF hydroxylases. Provided none high expression HIF hydroxylases, the 5-year
survival was 80% vs. 23% if all four were highly expressed (HR=6.48, CI 95% 2.23–18.8, P=0.001).
Conclusions: HIF hydroxylases are, in general, poor prognosticators for NSCLC survival. PHD1 and PHD2 are independent
negative prognostic factors in NSCLC. Moreover, there is an additive poor prognostic impact by an increasing number of
highly expressed HIF hydroxylases.
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Introduction
Due to its high prevalence and poor survival, lung cancer is the
leading cause of cancer-related deaths [1]. Eighty to 85% of lung
cancers are of non-small cell type (NSCLC). At early stages
NSCLC is potentially curable by surgery [2], but even among
tumor-resected patients lung cancer mortality remains high. There
is a need for better prognostic and predictive factors, incorporated
with clinicopathological features, for treatment stratification, as
well as new treatment options [2].
Hypoxia is a feature of many NSCLC tumors [3] and the ability
of tumor cells to adapt to a reduced oxygen and nutrient supply is
vital for their survival [4]. When oxygen tension is reduced, the
HIF transcription factors, composed of the subunits HIFa (HIF1a,
HIF2a or HIF3a) and HIFb, are at the heart of these mechanisms.
They control the cellular expression of hundreds of target genes,
which makes the tumor cell capable of surviving in a hypoxic
microenvironment [5]. Regulation of the HIF activity is mainly
controlled by the half-life of the HIFa-subunit, which is tightly
controlled by the oxygen dependent hydroxylation by HIF
hydroxylases. Under normoxia, HIFa is hydroxylated by prolyl
hydroxylases (PHD1, PHD2 and PHD3) and factor inhibiting HIF
(FIH). Hydroxylation through PHDs enables binding with von
Hippel-Lindau (VHL) tumor suppression protein with subsequent
targeting of HIFa for proteosomal degradation by ubiquitation
[6,7]. All PHDs have the same function, but appears to have
different specificities for various hydroxylation sites [8]. PHD2 is
the most abundant form and the main regulator of HIF1 activity,
whereas PHD3 more efficiently regulates HIF2a [8,9]. Together
with the transcriptional modifyer FIH, these are known as HIF
hydroxylases. These serve the function as oxygen sensors in the
vital cellular oxygen homeostasis [8,10].
Although HIF hydroxylases recently were recognized as
important players in cancer biology by interfering with angiogen-
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tumorigenesis is poorly defined. They have been proposed as both
tumor suppressors and drivers of tumorigenesis [12]. Antibodies
for detection of these proteins in paraffin-embedded human tissues
have recently been developed and validated [13]. Only one
previous study has evaluated these HIF hydroxylases in NSCLC
tumors, but without assessing their prognostic relevance [14].
We aimed to pioneer the first comprehensive prognostic impact
evaluation of the HIF hydroxylases in a large unselected NSCLC
cohort. Studies evaluating the clinical significance of these markers
in malignancy are limited, and they have a potential role as
therapeutic targets [12].
Results
Patient characteristics
The patients’ demographic, clinical and histopathological data
are presented in Table 1. The median follow-up time of survivors
was 86 months (range 48–216). The median patient age was 67
(range 28–85), 75% were male, 95% had performance status 0–1
and 95% were present or previous smokers. The NSCLC tumors
comprised 191 squamous cell carcinomas (SCC), 113 adenocar-
cinomas (AC) including 18 bronchioalveolar carcinomas (BAC),
and 31 large-cell carcinomas (LCC).
Expression of HIF hydroxylases
All HIF hydroxylases were detectable for scoring in NSCLC
tumor cells. In the surrounding tumor stroma some expression was
seen, especially in endothelial cells. However, in our TMA-sections
it was not scorable. The localization of staining in tumor cells was
predominantly cytoplasmic although there was some nuclear
staining for all antibodies. Nuclear staining, however, was almost
always accompanied by a strong cytoplasmic staining and the
scarce number of cores with exclusive nuclear staining was not
statistically evaluable for prognosis. A dominant intensity (.50%
of viable tumor cells) was evaluable for all tumor cores with only
minor heterogeneity within cores. PHD3 expression in BACs was
the only exception, where a more pronounced heterogeneity was
observed with some tumor cells strongly expressing PHD3.
The expression in normal lung and surrounding stroma was
fairly similar to the findings by Giatromanolaki et al [14] except
for the stronger granulated positivity in peritumoral pneumocytes
compared to pneumocytes in normal lung.
Correlations
There were no correlations between HIF hydroxylases and the
clinicopathological variables in Table 1, but weak correlations
between various HIF hydroxylases were observed; PHD1 vs.
PHD2 (r=0.107, P=0.057), vs. PHD3 (r=0.079, P=0.16) and
vs. FIH (r=0.14, P=0.013); PHD2 vs. PHD3 (r=0.083,
P=0.137) and PHD2 vs. FIH (r=0.183, P=0.001); PHD3 vs.
FIH (r=0.051, P=0.363).
When the HIF hydroxylases were compared with tumor cell
expression of molecular markers previously published by this group
[15–19], the following correlations were observed; PHD1 vs.
VEGF-A (r=0.27, P=,0.001) and PDGF-A (r=0.23, P,0.001);
PHD2 vs. VEGFR3 (r=0.23, P,0.001); FIH vs. VEGFR3
(r=0.25, P,0.001), Notch4 (r=0.26, P,0.001), HIF2a (r=0.22,
P,0.001), LDH5 (r=0.22, P,0.001), Ang-1 (r=0.21, P,0.001),
Ang-4 (r=0.24, P,0.001), and Tie-2 (r=0.22, P,0.001).
Univariate analyses
Results regarding the clinicopathological variables are presented
in Table 1. WHO performance status (P=0.013), differentiation
(P,0.001), surgical procedure (P=0.004), pathological stage
(P,0.001), T-status (P,0.001), N-status (P,0.001) and vascular
infiltration (P,0.001) were significant prognostic factors (Table 1).
Data on the association between molecular markers and DSS
are given in Table 2 and Figure 1. For all of the HIF hydroxylases,
high tumor cell expression was significantly associated with poor
survival; PHD1 (P=0.023), PHD2 (P=0.013), PHD3 (P=0.018)
and FIH (P=0.033).
When assessing the co-expression variable of all the HIF
hydroxylases, there was a significant additive pattern with a
progressively worse survival with the increasing number (0–4) of
highly expressed HIF hydroxylases (Table 2 and Figure 2).
Multivariate analyses
Results of the multivariate analyses are presented in Table 3. In
Model 1 we found high tumor cell expression of the PHD2
(HR=2.03, CI 95% 1.20–3.42, P=0.008) and PHD1 (HR=1.45,
CI 95% 1.01–2.10, P=0.047) to be significant independent
prognosticators for DSS in addition to several clinicopathological
variables (tumor status, P,0.001; nodal status, P,0.001; perfor-
mance status, P=0.001; vascular infiltration; P=0.002; differen-
tiation, P=0.006). High tumor cell expression of PHD3
(P=0.058) and FIH (P=0.15) did not, however, reach statistical
significance.
In model 2, we found a gradually increasing hazard ratio for
lung cancer death in patients with an increasing number of highly
expressed HIF hydroxylases in comparison to those with no high
expression of hydroxylases (Table 3). Patients with high tumor cell
expression of all four HIF hydroxylases had a HR of 6.48 (CI
2.23–18.8, P=0.001).
Discussion
We present the first large-scale study evaluating the prognostic
impact of HIF hydroxylases in surgically resected NSCLC. Using
validated antibodies, in this large unselected cohort, we found that
high expression of all the HIF hydroxylases were prognosticators
for poor survival, with PHD1 and especially PHD2 as independent
negative prognostic factors. In addition, there was an additive poor
prognostic impact by the increasing number (0–4) of highly
expressed HIF hydroxylases.
A limited number studies have evaluated the expression of HIF
hydroxylases in various cancers [13,20–27] including one in
NSCLC [14]. Only three have assessed survival outcome in
relation to expression of these HIF hydroxylases [21–23], none in
NSCLC. In general, IHC-studies have found increased, but
variable staining of PHDs and FIH in human cancers [12].
Corroborating previous studies [21,22,24,25,27], we did not find
the expected simplistic association between high HIF hydroxylase
expression and low HIFa expression, or vice versa, as expected
from earlier functional studies [12]. Consistent with Giatromano-
laki et al [14], the most significant, though weak, correlations were
between PHD1-FIH and PHD2-FIH. Expression patterns were
also similar, but in our TMA cores there were no clear examples of
nuclear expression without an accompanying strong cytoplasmic
expression.
In pancreatobiliary ampullary adenocarcinoma, Gossage et al.
observed that high PHD3 expression was significantly associated
to a worse overall survival [23]. There was also a similar trend for
PHD2. In pancreatic endocrine tumors, Couvelard and colleagues
found high nuclear staining of PHD1 and PHD3 and stromal
staining of FIH to correlate with a worse survival [22]. In prostate
cancer, Boddy et al. did not observe any associations between
PHDs and survival or PSA recurrence [21]. To summarize, few
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NSCLC patients (univariate analyses; log rank test).
Characteristic
Patients
(n)
Patients
(%)
Median survival
(months)
5-Year survival
(%) P
Age
#65 years 156 47 83 55 0.34
.65 years 179 53 NR 60
Sex
Female 82 25 190 63 0.20
Male 253 75 83 56
Smoking
Never 15 5 19 43 0.23
Current 215 64 NR 60
Former 105 31 71 54
Performance status
PS 0 197 59 NR 63 0.013
PS 1 120 36 64 52
PS 2 18 5 25 33
Weight loss
,10% 303 90 127 58 0.71
.1 0 % 3 21 09 8 5 7
Histology
SCC 191 57 NR 66 0.08
AC 113 34 54 45
LCC 31 9 98 56
Differentiation
Poor 138 41 47 47 ,0.001
Moderate 144 43 190 64
Well 53 16 NR 68
Surgical procedure
Lobectomy+Wedge* 243 73 190 61 0.004
Pneumonectomy 92 27 37 47
Pathological stage
I 157 47 190 71 ,0.001
II 136 40 61 51
IIIa 42 13 17 23
Tumor status ,0.001
1 8 52 51 9 0 7 4
2 188 56 84 57
3 6 21 92 5 3 6
Nodal status
0 232 69 190 66 ,0.001
1 7 62 33 5 4 3
22 7 8 1 8 1 8
Surgical margins
Free 307 92 190 58 0.29
Not free 28 8 47 47
Vascular infiltration
No 284 85 190 58 ,0.001
Y e s 5 11 52 7 3 2
*Wedge, n=10.
Abbreviations: NR=not reached; PS=Performance status; SCC=Squamous cell carcinoma, LCC=Large-cell carcinoma; AC=Adenocarcinoma (including
bronchioloalveolar carcinoma).
doi:10.1371/journal.pone.0023847.t001
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hydroxylase expression and clinical outcome, and the positive ones
have revealed an association with reduced survival.
The earlier functional studies on HIF hydroxylases identified
them as downregulators of HIFa. The fact that high expression of
HIF hydroxylases serve as poor prognosticators for DSS seemingly
contradicts the canonical function as inhibitors of HIFa, which has
consistently been shown to be a tumor progression marker [5].
Several experimental studies have recently tried to elucidate
essential roles of HIF hydroxylases in tumor progression. In line
with our data, Henze et al. found that inhibition of PHDs
significantly reduced glioblastoma cell survival and that PHD
inhibition increased hypoxic cell death as well as death induced by
chemotherapeutics [24]. Furthermore, the PHD/HIF regulatory
axis was postulated as a novel therapeutic target to disable a
tumor’s ability to adjust to hypoxic conditions and maintain cell
survival [24].
Mazzone et al did functional studies of the stromal role of
PHD2 in tumorigenesis by implanting pancreatic tumors in
immunocompromized PHD2
+/2 mice [28]. Surprisingly, the
heterozygous deficiency of PHD2 led to improved endothelial
lining, vessel maturation, tumor perfusion and oxygenation with a
subsequent inhibition of tumor cell invasion, intravasation and
metastasis. The experimentally reduced available level of PHD2 in
the host, actually seemed to reduce the malignancy of implanted
tumors. Besides, Ginouves et al. found that chronic hypoxia (24 h
to 7 days) increased the pool of PHDs and overactivated all three
isoforms thereby ‘‘desensitizing’’ HIFa and protected cells from
necrosis [29]. Desensitizing HIFa proved to be required since all
experimental cells died if HIF1a expression was not reduced
during chronic hypoxia. Using implanted colon carcinoma tumors
with decreased PHD2 expression in mice, Chan et al observed that
tumors grew dramatically faster than control tumors and that
PHD2 loss also induced angiogenesis and recruitment of bone
marrow-derived cells. [30]. In pancreatic cancer, Su et al. recently
reported that PHD3 overexpression mediated tumor cell growth
and invasion [26]. Overexpression of PHD1 was shown by Erez et
al. to inhibit tumor growth [31].
In light of these functional studies on HIF hydroxylases in
cancer, it is difficult to decipher why elevated expression levels of
HIF hydroxylases are associated with a poor survival. The studies
so far do not give us a clear functional explanation of the function
of HIF hydroxylases in cancer. To quote Jokilehto and Jaakkola in
a recent review, ‘‘given the uncertainties in specific PHD function, their role
in cancer is inconclusive at the best’’ [12].
HIF hydroxylases appear to be important players in tumor
biology. As high cellular levels of HIF hydroxylases seem to be
important in the malignant phenotype, they may qualify as
potential therapeutic targets in NSCLC. Due to the basic
understanding of HIF hydroxylase functions, Nagel et al. recently
proposed inhibition of HIFa through activation of PHDs.
However, if PHDs are vital in disease progression, in consistency
with our findings, these oxygen sensors would rather be a target of
inhibition. [32]. Although several inhibitors of HIF hydroxylases
Table 2. Expression of oxygen sensors in tumors as prognostic factors for disease-specific survival in 335 NSCLC patients
(univariate analyses; log-rank test).
Characteristics
Patients
(n) Patients (%) Median survival (months) 5-year survival (%) P
PHD1 0.023
High 150 45 71 53
Low 171 51 190 65
Missing 14 4
PHD2 0.013
High 258 77 83 55
Low 68 20 NR 71
Missing 9 3
PHD3 0.018
High 49 15 44 43
Low 274 82 190 61
Missing 12 3
FIH 0.033
High 85 25 64 50
Low 243 73 NR 60
Missing 7 2
Co-expression of oxygen sensors ,0.001
03 6 1 1 N R 8 0
1 106 32 NR 65
2 112 33 190 57
35 2 1 5 5 7 4 8
4 10 3 24 23
Missing 19 6
doi:10.1371/journal.pone.0023847.t002
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registered on www.clinicaltrials.com [32].
In conclusion, we found high expression of all four HIF
hydroxylases to be indicators of poor prognosis in NSCLC with
PHD2 as the most significant prognostic marker. In addition,
patients could be stratified in highly diverging prognostic
subgroups according to the additive number of highly expressed
HIF hydroxylases. We suggest HIF hydroxylases as possible
molecular markers for prognostic stratification in addition to
already incorporated clinicopathological prognosticators. We also
propose them as potential targets for cancer growth inhibition.
Materials and Methods
Patients and Tissues
Retrospectively, we identified 371 patients who were surgically
tumor-resected with pathological stage I to IIIA NSCLC at the
University Hospital of North Norway and Nordland Central
Hospital between 1990 and 2004. Primary tumor tissue was
collected from the archives of the two pathology departments.
After the necessary exclusion of 36 patients due to inadequate
paraffin-embedded fixed tissue blocks (n=13), other malignancy
within the 5 years prior to diagnosis (n=13) or having received
radiotherapy or chemotherapy prior to surgery (n=10), we were
left with 335 eligible patients with complete demographic and
clinicopathological data. The pathological data were revised
according to the 7th edition of UICC TNM classification of lung
cancer [33]. Adjuvant chemotherapy was not introduced in
Norway in this period (1990–2004). The last disease-specific
survival (DSS) update was done in November 2008. The
Norwegian Data Inspection Board and The Regional Committee
for research ethics have approved the study.
Microarray construction
Duplicate 0.6 mm core biopsies from the most representative
areas of tumor cells (neoplastic epithelial cells) and tumor stroma
Figure 1. Disease-specific survival according to HIF hydroxylase expression. Disease-specific Kaplan-Meier survival curves according to:
A) PHD1, B) PHD2, C) PHD3 and D) FIH in resected NSCLC patients. The P-value is according to the log-rank test.
doi:10.1371/journal.pone.0023847.g001
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instrument (Beecher Instruments, Silver Springs, MD,USA).
Normal lung tissue localized distant from the primary tumor as
well as lung tissue samples from 20 patients without any history of
malignancy were also sampled. Eight tissue microarray blocks
(TMAs) were constructed to include all the cores. The detailed
methodology has been reported previously [16,17].
Immunohistochemistry
Antibodies developed and published by the Nuffield Depart-
ment of Clinical Laboratory Sciences at the University of Oxford,
UK were donated [13,14]. These were anti-PHD1 (PHD112,
mouse monoclonal), anti-PHD2 (366G/76, mouse monoclonal,
not diluted), anti-PHD3 (EG188e, mouse monoclonal, not diluted)
and anti-FIH (162c/D6, mouse monoclonal, 1:5). Probably due to
low antibody concentration against PHD1 when experiments were
done, we did not succeed in attaining a strong enough staining
with the donated PHD1 antibody. The PHD-1 antibody in this
study was therefore acquired from Abcam (ab82884, PHD112/
G7, mouse monoclonal, 1:50). The 4 mm TMA sections
containing tissue cores were deparaffinized with xylene and
rehydrated with ethanol before being subjected to the antibodies.
Negative controls were simultaneously performed for all
antibodies by omitting the primary antibody. For the commer-
cially antibody for PHD1 we used normal testis as a positive
control. For the donated antibodies, staining patterns in tumor and
normal lung were compared to what has been published earlier
regarding staining with these antibodies in NSCLC and lung
tissues to ensure the proper staining with these antibodies [13,14].
Validation on transfected cell lines with positive and negative
controls has previously been published [13,14].
Antigen retrieval was done manually for all antibodies except
PHD1. For PHD2 and FIH, antigen retrieval was done by
placing the specimens in 0.01 M citrate buffer at pH 6.0 and
exposed to microwave heating of 20 minutes at 450 W. The
antigen retrieval for PHD3 was the same except for the buffer
which was a 10 mom Tris/1 mM EDTA buffer at pH 9.0. All
donated antibodies were incubated at room temperature (<20uC)
overnight except for FIH where the primary antibody was
incubated for 30 min in room temperature. The methods were
adapted from the donators. For PHD1 we used the Ventana
Benchmark XTH (Ventana Medical Systems Inc.;Illkirch,
France), procedure ultraview DAB v3 with automatic antigen
retrieval with CC1 mild (30 min). Finally, all slides were
counterstained with hematoxylin to visualize the nuclei.
Scoring of immunohistochemistry
Viable parts of each anonymized core were scored indepen-
dently and semiquantitatively by two pathologists (S.A.S and
K.A.S) by light microscopy. When assessing a variable in a given
core, the pathologists were blinded to the outcome and score of the
other observer. Only the neoplastic cell compartment (tumor cells)
was scored in this study as there was no scorable expression in the
surrounding tumor stroma (stromal cells). The dominant staining
intensity in tumor was scored as: 0=negative, 1=weak,
2=intermediate or 3=strong (Figure 3). Only cytoplasmic
staining was scored. Interindividual variability with respect to
IHC-scoring was evaluated on the current material in a previous
paper (r=0.95, range 0.93–0.98) [17].
A mean score was calculated for the two tumor cell cores in
each individual. In tumor, high expression was defined as =3 for
PHD1, PHD3 and FIH, and $2.0 for PHD2. Similar scoring
methods have been used in our previous IHC-scoring studies
[17,34,35] and by others [36]. Optimal statistical cut-off levels for
high and low expression were used.
Statistical methods
The statistical analyses were done using the SPSS 17.0.0
package (Chicago, IL). The x2 test and Fishers exact tests were
used to examine the associations between molecular marker
expressions and the clinicopathological markers. r-values are the
Spearman’s rank correlation coefficient. Plots of the DSS,
according to marker expressions, were drawn using the Kaplan-
Meier method, and the statistical significance between survival
curves was assessed by the log rank test. The survival curves were
terminated at 146 months, due to less than 10% of patients at risk
after this point. The chosen endpoint, DSS, was calculated from
the time of surgery to the time of lung cancer death.
In the first model of the multivariate analysis (Model 1), all
significant variables from the univariate analyses (except surgical
procedure and pathological stage) were entered in a backward
stepwise Cox regression analysis with a probability for stepwise
entry and removal at 0.05 and 0.10, respectively. A P,0.05 was
considered statistically significant for all analyses. In the second
model for multivariate analysis (Model 2), all the significant
clinicopathological variables (except surgical procedure and
pathological stage) were entered as well as the co-expression
variable. The co-expression variable, including all of the four HIF
hydroxylases, was stratified by the number of HIF hydroxylases
demonstrating high expression.
Ethics statement
The Norwegian Data Inspection Board and The Regional
Committee for research ethics have approved the study.
Information and subsequent written consent from patients was
considered, but as this was a retrospective study with more than
half of patients deceased, the rest of the patients having to
reminded about the death rate of the disease and the possible
raising of unrealistic hope for the individual, they specifically
waived the need for consent.
Figure 2.Disease-specific survival accordingto theco-expression
of HIF hydroxylases. Disease-specific Kaplan-Meier survival curves
according to the sum of HIF hydroxylases with a high expression in
resected NSCLC patients. The P-value is according to the log-rank test.
doi:10.1371/journal.pone.0023847.g002
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Model 1
(all significant variables entered)
Model 2
(Clinicopathological and
co-expression variable entered)
Factor Hazard Ratio 95% CI P Hazard Ratio 95% CI P
Tumor status ,0.001* ,0.001*
11 1
2 1.72 1.02–2.89 0.041 1.95 1.14–3.36 0.015
3 3.27 1.84–5.81 ,0.001 3.72 2.03–6.85 ,0.001
Nodal status ,0.001* ,0.001*
01 1
1 1.92 1.25–2.94 0.003 1.94 1.26–2.97 0.002
2 3.30 1.95–5.59 ,0.001 3.03 1.75–5.23 ,0.001
Performance status 0.001* 0.001*
ECOG 0 1 1
ECOG 1 2.02 1.37–2.98 ,0.001 2.03 1.37–2.99 ,0.001
ECOG 2 2.16 0.95–4.91 0.065 2.10 0.92–4.77 0.077
Vascular infiltration 0.002 0.002
No 1 1
Yes 2.08 1.29–3.34 2.13 1.31–3.49
Differentiation 0.006* 0.006*
Well 1 1
Moderate 1.89 0.97–3.69 0.061 1.62 0.83–3.14 0.16
Poor 1.02 0.51–2.02 0.096 0.85 0.42–1.72 0.65
PHD1 0.047
Low 1
High 1.45 1.01–2.10
PHD2 0.008
Low 1
High 2.03 1.20–3.42
Co-expression{ ,0.001*
0 1
1 1.95 0.81–4.66 0.135
2 2.05 0.86–4.89 0.105
3 4.13 1.69–10.1 0.002
4 6.48 2.23–18.8 0.001
*Overall significance as a prognostic factor.
{The co-expression variable, included all of the four oxygen sensors and was stratified by the total number of oxygen sensors with a high expression.
Grey boxes indicate variables not entered in the analysis.
doi:10.1371/journal.pone.0023847.t003
Figure 3. Immunohistochemical staining. Immunohistochemical analyses of NSCLC representing high and low intensities for tumor cell
expression of PHD1, PHD2, PHD3 and FIH.
doi:10.1371/journal.pone.0023847.g003
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